The release of C5a in complement-activated serum does not require C6.
The influence of terminal complement components on the generation and release of the complement C5a fragment was investigated by comparing the levels of C5a in complement-activated serum with the levels of C5a produced in serum depleted of complement C6. In order to investigate the release of C5a, a modified C5a assay was developed that utilizes an anti-C5b monoclonal antibody to remove C5, C5b, and C5b-C5a complexes from samples prior to C5a assay. The modified assay was developed because the standard methodology, which includes an acid-precipitation step designed to dissociate C5a and C5b, cannot distinguish free C5a from the C5a that is bound to C5b. Therefore, the standard methodology is not capable of monitoring the influence of terminal components on C5a/C5b dissociation. Levels of C5a were measured in complement-activated whole human serum, in serum depleted of C6, and in serum containing inhibitory levels of anti-C6 Fab using both the modified C5a assay and the standard methodology. Sera were complement-activated with either zymosan to activate the alternative complement pathway or with antibody-coated sheep erythrocytes to activate the classical pathway. The levels of free C5a in C6-depleted sera after activation were equivalent to the C5a levels in activated whole serum, indicating that C6 is not required for the release of C5a from C5b. In addition, the quantity of C5a detected in zymosan-activated sera using the standard acid-precipitation methodology was greater than C5a levels when assayed using the modified immunoadsorption technique, confirming that acid-treatment enhances the C5a dissociation and promotes C5a recovery. Since the other terminal components, C7, C8, and C9, bind to C5b only after C5b only after C6 is bound, these results indicate that none of the terminal components are required for the release of C5a. Although the terminal components could influence the rate of C5a release, the quantity of C5a released in serum was entirely independent of terminal components.
Biesecker
G
G
Department of Pathology, Hahnemann University, Philadelphia, PA 19102.
Wagner
J L
JL
Hugli
T E
TE
D000818:Animals; D000911:Antibodies, Monoclonal / Q000502:physiology; D003167:Complement Activation; D003182:Complement C5 / Q000096:biosynthesis / Q000276:immunology / Q000378:metabolism*; D015936:Complement C5a; D050776:Complement C5b; D003183:Complement C6 / Q000276:immunology / Q000502:physiology*; D006801:Humans; D007163:Immunosorbent Techniques; D051379:Mice; D008807:Mice, Inbred BALB C; D009504:Neutrophils / Q000201:enzymology; D009195:Peroxidase / Q000097:blood; D015054:Zymosan
D000911:Antibodies, Monoclonal; D003182:Complement C5; D003183:Complement C6; D015936:Complement C5a; D050776:Complement C5b; D015054:Zymosan; D009195:Peroxidase